Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.
Đang tải nội dung...
Content sourced from
MarketWatch
11:17 - 06/04/2026
Previous
JPMorgan CEO Jamie Dimon in annual letter cites risks in geopolitics, AI and private markets
Next
Điện Biên thử nghiệm UAV phun phân bón cho cây cà phê
VnExpress